Neutral
GlobeNewsWire
25 days ago
PrimeGen US, Inc. Announces Proposed Business Combination with DT Cloud Star Acquisition Corporation at an Implied Equity Value of Approximately $1.5 Billion to Advance Its Stem Cell Research and Development Efforts
SANTA ANA, CALIFORNIA, Feb. 04, 2026 (GLOBE NEWSWIRE) -- PrimeGen US, Inc. (“PrimeGen US" or the "Company”), a pioneering biotech company advancing innovative stem cell and exosome therapies, today announced it has entered into a definitive business combination agreement dated as of February 2, 2026 (the "Business Combination Agreement") with DT Cloud Star Acquisition Corporation (“DT Cloud Star”), a publicly traded special purpose acquisition company (Nasdaq: DTSQ). The transaction implies an equity value for PrimeGen US of approximately $1.5 billion and is expected to provide access to the public markets capital, which the combined company intends to use to advance clinical development, regulatory activities, and if approved, potential commercialization of its lead programs.